Results 201 to 210 of about 33,569 (238)
Some of the next articles are maybe not open access.
Management of Women With BRCA Mutations
JAMA, 2011Ms E, a 41-year-old BRCA1 mutation carrier, was diagnosed 4 years ago as having breast cancer and opted for breast-conserving therapy. Prior to receiving chemotherapy, she harvested her eggs through in vitro fertilization and subsequently used preimplantation genetic diagnosis; 3 months ago she delivered a healthy boy.
openaire +2 more sources
Journal of Clinical Oncology, 2008
1534 Background: Much attention has been focused on screening and risk reduction, including prophylactic mastectomy (PM) or oophorectomy (PO) in BRCA+ mutation carriers (Rebbeck 1999, Eisen 2005, Kauff 2007). In families with a known BRCA mutation (BRCA+) or a history of hereditary breast cancer (BC) or ovarian cancer (OC), relatives in whom a mutation
S. Verma +3 more
openaire +1 more source
1534 Background: Much attention has been focused on screening and risk reduction, including prophylactic mastectomy (PM) or oophorectomy (PO) in BRCA+ mutation carriers (Rebbeck 1999, Eisen 2005, Kauff 2007). In families with a known BRCA mutation (BRCA+) or a history of hereditary breast cancer (BC) or ovarian cancer (OC), relatives in whom a mutation
S. Verma +3 more
openaire +1 more source
Annals of Surgical Oncology, 2014
This study evaluates whether nodal status differs between breast cancer patients with BRCA mutations and those confirmed not to harbor mutations.A prospective database identified patients with breast cancer who underwent genetic testing and axillary staging.
Shahrbanoo F, Noori +8 more
openaire +2 more sources
This study evaluates whether nodal status differs between breast cancer patients with BRCA mutations and those confirmed not to harbor mutations.A prospective database identified patients with breast cancer who underwent genetic testing and axillary staging.
Shahrbanoo F, Noori +8 more
openaire +2 more sources
Progress in BRCA -Mutated Ovarian Cancer
New England Journal of Medicine, 2018The article by Moore et al.1 in this issue of the Journal is the culmination of a long march for olaparib in the treatment of BRCA-mutated high-grade serous ovarian cancer — one that began with its...
David R, Spriggs, Dan L, Longo
openaire +2 more sources
Targeting BRCA-mutated tumors in mitosis
Nature Cancer, 2021Demis Menolfi, Shan Zha
openaire +2 more sources
Obesity as a promoter in BRCA mutation carriers
Nature Reviews Cancer, 2023openaire +2 more sources

